Visual Abstract

Background: The Medtronic MiniMed™ AHCL system that autocorrects to 120mg/dL every five minutes and has an automated basal target of 100mg/dL or 120mg/dL has demonstrated improved A1C and time in range1,2 or improved time in closed-loop control,3 compared to open-loop run-in or control. Glycemic outcomes of study participants who used a different baseline therapy (HCL, SAP or CSII) during the MiniMed™ AHCL pivotal trial were analyzed.

Methods: Across 16 sites, participants (N=157, 14-75 years) with T1D underwent a baseline run-in period (~2 weeks) of HCL, SAP or CSII followed by a 90-day study phase with AHCL automated basal and auto-correction. An exploratory analysis compared the mean sensor glucose and percentage of time spent across glucose ranges during the baseline run-in and AHCL-study phase for each cohort.

Results: Glycemic outcomes for the overall group and each cohort are shown in the table. Significant changes were observed from run-in to study period for the overall group. The glycemic outcomes that were achieved were similar regardless of the baseline therapy.

Conclusion: These MiniMed™ AHCL pivotal trial data demonstrate that the system achieves robust glycemic improvement regardless of baseline therapy.

graphic
View largeDownload slide
Disclosure

J. Shin: Employee; Self; Medtronic. X. Chen: None. M. Liu: None. S. Huang: None. T. L. Cordero: Employee; Self; Medtronic. A. S. Rhinehart: Employee; Self; Medtronic, Stock/Shareholder; Self; AstraZeneca, Lexicon Pharmaceuticals, Inc., Medtronic. R. Vigersky: Employee; Self; Medtronic.

Funding

Medtronic

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.